Can You Take Orlistat With Wegovy at the Same Time?

How do orlistat and Wegovy actually work, and why does that matter here?

Orlistat is a lipase inhibitor. It works in the digestive tract by blocking the enzymes that break down dietary fat, meaning roughly a third of the fat you eat passes through unabsorbed. That is its entire mechanism, local, gut-based, with no action on appetite hormones or the brain. The side effects follow logically from that: oily or loose stools, urgency, and bowel discomfort, particularly if meals are high in fat. The NHS medicines page on orlistat sets this out clearly alongside its contraindications.

Wegovy is a different proposition altogether. Semaglutide, its active ingredient, is a GLP-1 receptor agonist. It mimics a gut hormone to reduce appetite, increase the sensation of fullness, and slow how quickly food moves from the stomach into the small intestine. Its effects are systemic rather than local. The side-effect profile is also GI-heavy: nausea, vomiting, diarrhoea and constipation are the most commonly reported effects, especially in the early weeks of treatment or after a dose increase. The NHS overview of semaglutide covers these in detail.

So both medicines share a significant gastrointestinal burden, despite working in completely different ways. That overlap matters when someone asks whether they can run them together. The short answer is that you would be stacking two GI-demanding treatments, and the likely result is a harder time tolerating either.

Is there a safety concern with taking orlistat and Wegovy together?

This is a question our prescribers hear most weeks, often from people who were already established on orlistat when they became interested in a GLP-1 medicine, or vice versa. The concern is not a dramatic drug-drug interaction in the pharmacological sense, orlistat does not alter semaglutide's absorption in the way some oral medicines can. Wegovy is an injection, so orlistat's effect on gut absorption does not directly reduce how much semaglutide reaches the bloodstream.

The bigger issue is tolerability. Both medicines commonly cause loose stools, diarrhoea and stomach discomfort. Running them in parallel is very likely to compound those effects significantly. For many people, even one of these treatments alone is a challenge to adjust to in the first weeks. Adding the other simultaneously creates a practical barrier to adherence and, in some cases, risks dehydration from persistent diarrhoea.

There is also a question of necessity. Wegovy on its own, within the context of lifestyle changes, already produces meaningful reductions in body weight, the STEP 1 trial reported an average reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. Adding orlistat on top is unlikely to improve on that in a clinically meaningful way, particularly when the costs to comfort and adherence are factored in. A prescriber reviewing your case would weigh up what you are already on before recommending any change. You can explore what the wider weight-loss treatment landscape looks like if you are earlier in that decision.

What should you do if you are already taking orlistat and want to start Wegovy?

The practical path is straightforward: tell your prescriber. If you are already taking orlistat (whether through a GP, another clinic, or an over-the-counter prescription) that information needs to be part of your consultation before a GLP-1 medicine is considered. At nume, every consultation is read personally by a GPhC-registered Independent Prescriber on the same day; they can review what you are currently taking and make a recommendation about how to manage the transition, whether that means stopping orlistat first, completing a wash-out period, or another approach.

Stopping orlistat abruptly is generally not harmful the way stopping some other medicines can be, but you should not make that decision based on an article alone. If your orlistat was prescribed by your GP, it is also worth letting them know you are considering a GLP-1 medicine, this is in line with good practice, and the NHS England guidance on weight management injections recommends GP notification as part of responsible prescribing. The eligibility picture for Wegovy, including which BMI thresholds apply, is worth reviewing separately too, the BMI requirements for Wegovy page covers this in plain terms.

If you are thinking about other supplements or medicines alongside Wegovy more broadly, it is worth reading about creatine and Wegovy, checking the naproxen interaction page for a sense of how these questions are typically approached, or finding out whether collagen supplements are suitable to take alongside Wegovy.

Can you switch from orlistat to Wegovy rather than take both?

For most people, switching is the more realistic and better-tolerated path. Orlistat has been available for many years; Wegovy, and the clinical evidence behind it, represents a more recent category of treatment with a different mechanism and, in the trial data, greater average weight loss. That does not mean Wegovy is right for everyone, eligibility, health history, how well you tolerated orlistat, and your prescriber's clinical assessment all shape what is appropriate.

If you are thinking about making that switch, the starting point is a fresh consultation rather than simply stopping one and starting the other. A prescriber needs to assess your current situation, confirm Wegovy eligibility, and support you through the early dose titration period. The GLP-1 family works quite differently from orlistat, and the first few weeks typically involve adjustment, the guide to starting Wegovy covers what that looks like practically.

For a fuller picture of how Wegovy works, who it is licensed for, and what the evidence shows, the Wegovy overview is the right place to start. And if you are ready to talk to a prescriber about your options, a free consultation with our clinical team is the natural next step, no commitment, just a proper clinical review.